EGFR and neoplasm: The same study provided evidence of a correlation between EGFR gene mutations and a noninflammatory tumor microenvironment with immune tolerance and weak immunogenicity, contributing to the poor response of NSCLCs to PD‐1 blockade, and found that EGFR mutation (EGFR‐mut) was negatively correlated with TMB.18